340 related articles for article (PubMed ID: 32891627)
1. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.
Lorenz EC; Lieske JC; Seide BM; Olson JB; Mehta R; Milliner DS
Am J Kidney Dis; 2021 May; 77(5):816-819. PubMed ID: 32891627
[TBL] [Abstract][Full Text] [Related]
2. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant.
Lorenz EC; Lieske JC; Seide BM; Meek AM; Olson JB; Bergstralh EJ; Milliner DS
Am J Transplant; 2014 Jun; 14(6):1433-8. PubMed ID: 24797341
[TBL] [Abstract][Full Text] [Related]
3. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M; Groothoff JW; Shasha-Lavsky H; Lieske JC; Frishberg Y; Simkova E; Sellier-Leclerc AL; Devresse A; Guebre-Egziabher F; Bakkaloglu SA; Mourani C; Saqan R; Singer R; Willey R; Habtemariam B; Gansner JM; Bhan I; McGregor T; Magen D
Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
[TBL] [Abstract][Full Text] [Related]
4. Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria.
Plumb TJ; Swee ML; Fillaus JA
Am J Kidney Dis; 2013 Dec; 62(6):1155-9. PubMed ID: 23830800
[TBL] [Abstract][Full Text] [Related]
5. Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.
Sas DJ; Mara K; Mehta RA; Seide BM; Banks CJ; Danese DS; McGregor TL; Lieske JC; Milliner DS
Pediatr Nephrol; 2024 Jan; 39(1):141-148. PubMed ID: 37458799
[TBL] [Abstract][Full Text] [Related]
6. Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center.
Soliman NA; Nabhan MM; Abdelrahman SM; Abdelaziz H; Helmy R; Ghanim K; Bazaraa HM; Badr AM; Tolba OA; Kotb MA; Eweeda KM; Fayez A
Nephrol Ther; 2017 May; 13(3):176-182. PubMed ID: 28161266
[TBL] [Abstract][Full Text] [Related]
7. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
[TBL] [Abstract][Full Text] [Related]
8. Effect of vitamin B6 supplementation on plasma oxalate and oxalate removal rate in hemodialysis patients.
Costello JF; Sadovnic MC; Smith M; Stolarski C
J Am Soc Nephrol; 1992 Oct; 3(4):1018-24. PubMed ID: 1450364
[TBL] [Abstract][Full Text] [Related]
9. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function.
Hillebrand P; Hoppe B
Pediatr Nephrol; 2020 Jul; 35(7):1227-1233. PubMed ID: 32274573
[TBL] [Abstract][Full Text] [Related]
10. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria.
Marangella M; Petrarulo M; Cosseddu D; Vitale C; Linari F
Am J Kidney Dis; 1992 Jun; 19(6):546-53. PubMed ID: 1595703
[TBL] [Abstract][Full Text] [Related]
11. [Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].
Jaeger P; Portmann L; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1986 Dec; 116(50):1783-6. PubMed ID: 3798070
[TBL] [Abstract][Full Text] [Related]
12. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1.
Illies F; Bonzel KE; Wingen AM; Latta K; Hoyer PF
Kidney Int; 2006 Nov; 70(9):1642-8. PubMed ID: 16955107
[TBL] [Abstract][Full Text] [Related]
13. Lumasiran: A Review in Primary Hyperoxaluria Type 1.
Kang C
Drugs; 2024 Feb; 84(2):219-226. PubMed ID: 38252335
[TBL] [Abstract][Full Text] [Related]
14. Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: A case report.
Villani V; Gupta N; Elias N; Vagefi PA; Markmann JF; Paul E; Traum AZ; Yeh H
Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28261895
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival on renal replacement therapy for primary hyperoxaluria type I.
Calzavara P; Marangella M; Petrarulo M; Ballanti P; Bonucci E; Calconi G; Maresca MC; da Porto A; Vianello A
Nephron; 1993; 63(2):217-21. PubMed ID: 8450916
[TBL] [Abstract][Full Text] [Related]
16. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study.
Hoppe B; Pellikka PA; Dehmel B; Banos A; Lindner E; Herberg U
Nephrol Dial Transplant; 2021 Jul; 36(8):1464-1473. PubMed ID: 32810261
[TBL] [Abstract][Full Text] [Related]
17. Treatment of primary hyperoxaluria type 1.
Gupta A; Somers MJG; Baum MA
Clin Kidney J; 2022 May; 15(Suppl 1):i9-i13. PubMed ID: 35592620
[TBL] [Abstract][Full Text] [Related]
18. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I.
Oppici E; Fargue S; Reid ES; Mills PB; Clayton PT; Danpure CJ; Cellini B
Hum Mol Genet; 2015 Oct; 24(19):5500-11. PubMed ID: 26199318
[TBL] [Abstract][Full Text] [Related]
19. Type 1 primary hyperoxaluria: A case report and focus on bone impairment of systemic oxalosis.
Pijnenburg L; Caillard S; Boivin G; Rizzo S; Javier RM
Morphologie; 2018 Mar; 102(336):48-53. PubMed ID: 29102553
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
